In summary, our data show that plasma MCP-1 levels were significantly elevated in T2D patients with asthma as compared with those without asthma, and these changes in the systemic MCP-1 related differentially with important biomarkers of inflammation and airway remodeling. This evidence concerns the gene CCL2 and asthma.